Healthcare [ 12/13 ] | Biotechnology [ 116/164 ]
NASDAQ | Common Stock
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors.
In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease.
It has a research collaboration agreement with CRISPR Therapeutics AG.
Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.58 Increased by +7.94% | -0.56 Decreased by -3.57% |
| Mar 21, 24 | -0.57 Increased by +14.93% | -0.59 Increased by +3.39% |
| Nov 9, 23 | -0.52 Increased by +10.34% | -0.67 Increased by +22.39% |
| Aug 10, 23 | -0.60 Increased by +1.64% | -0.68 Increased by +11.76% |
| May 11, 23 | -0.63 Increased by +20.25% | -0.70 Increased by +10.00% |
| Mar 16, 23 | -0.67 Increased by +2.90% | -0.64 Decreased by -4.69% |
| Nov 9, 22 | -0.58 Increased by +14.71% | -0.62 Increased by +6.45% |
| Aug 11, 22 | -0.61 Increased by +7.58% | -0.59 Decreased by -3.39% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -29.52 M Decreased by -8.06% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 10.54 M Increased by +N/A% | -27.75 M Increased by +21.76% | Decreased by -263.27% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -25.64 M Increased by +2.96% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -33.29 M Decreased by -20.57% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -27.32 M Decreased by -4.67% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -35.47 M Decreased by -55.48% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -26.43 M Decreased by -18.23% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -27.61 M Decreased by -28.21% | Decreased by N/A% Decreased by N/A% |